Dr. Le Poole will share incoming data from basic research that are relevant to the future application ofHSP70iQ435A in a clinical trials setting. Specifically she will test the consequences of CM treatment for the arrest and regression of vitiligo over a range of disease stages in a spontaneous mouse model of the disease. Dr. Le Poole will also arrange monthly update meetings with all stakeholders and provide input for the IND application from existing experimental materials acquired with NIH support, including blood skin and other tissue samples saved from mice and swine, to fulfill FDA requirements.
|Effective start/end date||9/22/17 → 8/31/20|
- Radikal Therapeutics Inc (Agmt 03/27/18//2R44AR065886-02A1)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (Agmt 03/27/18//2R44AR065886-02A1)